Brief: Inhibikase Therapeutics Initiates Development Of Second Generation C-Abl Inhibitors And Names Ikt-148009 As Risvodetinib
21/08/2023 13:33
Aug 21 (Reuters) -
* INHIBIKASE THERAPEUTICS INITIATES DEVELOPMENT OF SECOND
GENERATION C-ABL INHIBITORS AND NAMES IKT-148009 AS RISVODETINIB
Source text for Eikon: ID:nPn82gt2Pa
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary